Christian Bréchot, MD, PhD
Christian Bréchot, MD, PhD, is president of GVN and oversees the scientific stewardship of the Network. Serving in this role since September 2017 Dr. Bréchot brings his vast research, training and collaboration experience of over 30 years.
Dr. Bréchot works with GVN leadership and staff to ensure that the core objectives of the Network are upheld and strengthened, and the various ongoing and new programs reach their full effectiveness. He provides strategic leadership and guidance to GVN’s 59 Centers of Excellence and 11 affiliated laboratories in 34 nations of the world on evidence-based results oriented projects, partnerships, and global activities geared towards coalition building in virology.
Dr. Bréchot concurrently holds several positions. He currently is the Senior Associate Dean for Research in Global Affairs, Associate Vice President for International Partnerships and Innovation, and Professor in the Division of Infectious Disease, Department of Internal Medicine, at the University of South Florida (USF) Health Morsani College of Medicine. Additionally he also serves as the executive director of the Tampa-based Romark Laboratories Institute for Medical Research and is chief executive officer of The Healthy Aging Company.
With a proven track record in both the private and public sectors, his expertise spans research, innovation, and collaborative solutions. Prior to his current appoints Dr. Bréchot served as president of the Institut Pasteur, driving recruitment of eminent scientists, implementing an international multidisciplinary education and teaching program, and fostering collaborative research and training strategies with major universities and research organizations. During his tenure between October 2013 – September 2017, Dr. Bréchot strengthened the international network of 33 Pasteur Institutes to encompass a global scientific vision and positioning an ambitious and internationally oriented strategy for capacity development, technology transfer and fundraising. Dr. Bréchot has an intimate knowledge of research and innovation, especially in virology. He has demonstrated his ability to drive change at scale by building new programs and diversified funding models.
Dr. Bréchot’s research has been focused on viral hepatitis- hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer (Hepatocellular carcinoma: HCC) and to the molecular mechanisms that drive liver regeneration and cancer; in particular, cell cycle deregulation and the impact of oxidative stress. In 1989, he became full professor of Cell Biology and Hepatology, at the Paris Descartes University and in 1997 he was appointed head of the clinical department of liver diseases at the Necker-Enfants Malades Hospital. He was head of a research unit at the Necker Faculty of Medicine, jointly supported by Inserm, Paris Descartes University, and the Pasteur Institute. He was also head of the National Reference Centre on viral hepatitis from 1998 to 2001.
Dr. Bréchot has been a member of numerous scientific committees and societies and has authored over 350 articles published in medical and scientific journals. In addition, his research activities have led to 13 patents and contributed to the creation of three biotech companies: Rarecells, ALFACT Innovation and The Healthy Aging Company. From 2001 to 2007, Dr. Bréchot was General Director of Inserm, the French National Agency for biomedical research. In 2008, he was appointed as Vice-President of Medical and Scientific Affairs of the Institut Merieux company, where he merged the efforts of four sectors including in vitro diagnostics, preventive vaccines, therapeutic vaccines, as well as food safety (Biomérieux, Transgene, Merieux Nutrisciences, Advanced Bioscience Laboratory). He has also received the Académie Nationale de Médecine prize in 1996 and the Jean-Valade award in 2000
A French national, Dr. Bréchot earned his MD in 1975 from the Faculty of Medicine Broussais-Hotel, Dieu, Paris, France, and a Ph.D in Biochemistry from the University of Paris VII in 1985.